Retatrutide LY3437943 Peptide 2381089-83-2 | GMP Certified Weight Loss & Diabetes Research Peptide

Retatrutide/">Retatrutide/">Retatrutide/">Retatrutide/">Retatrutide/">Retatrutide/">Retatrutide/">Retatrutide/">Retatrutide (LY3437943) is a 39-amino acid peptide with triple agonist activity at glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). This innovative peptide features a C20 fatty diacid modification at position 17 and contains three non-coded amino acids that enhance its stability and biological activity.

The peptide backbone contains Aib2 (α-amino isobutyric acid) residues at positions 2 and 20 which provide exceptional stability against DPP4 cleavage while maintaining potent GIP activity. The inclusion of αMeL13 (α-methyl-L-leucine) at position 20 further enhances both GIP and glucagon receptor activity.

Retatrutide demonstrates significant potential for research applications in metabolic disorders including obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). Its triple mechanism of action includes stimulation of insulin release, suppression of appetite through central nervous system effects, and promotion of fat breakdown through enhanced lipolysis.

Current clinical trials are investigating Retatrutide's efficacy in various metabolic conditions. The peptide has shown promise in phase 2 and phase 3 trials for obesity management and type 2 diabetes treatment, with multiple ongoing studies evaluating its potential benefits.

The peptide is provided as a white to off-white solid with >99.5% purity as verified by HPLC analysis. Researchers should store the product at -80°C for long-term stability (2 years) or at -20°C for shorter storage periods (1 year).